BOPI 07 BR/2023 REPERTOIRE NUMERIQUE 18 Fig. 6 Consulter le mémoire ________________________________________ (11) 21041 (51) C07K 7/02 (2018.01); C07K 7/04 (2018.01) ; C07K 7/08 (2018.01) (21) 1202200275 - PCT/US2021/013463 (22) 14/01/2021 (30) US n° 62/961,624 du 15/01/2020 (54) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases. (72) FREDERICK, Brian Troy (US); SOMANI, Sandeep (US); BOURNE, Gregory Thomas (US); PATCH, Raymond (US); BHANDARI, Ashok (US); INGENITO, Raffaele (IT); COSTANTE, Roberto (IT); BRANCA, Danila (IT); BIANCHI, Elisabetta (IT) et SUN, Chengzao (US) (73) 1-JANSSEN BIOTECH, INC., 800/850 Ridgeview Drive, HORSHAM, Pennsylvania 19044 (US) et 2-PROTAGONIST THERAPEUTICS, INC., 7707 Gateway Boulevard, Suite 140, NEWARK, California 94560 (US) (74) S.C.P AKKUM, AKKUM & Associates, n° 1777, Rue 6.261, Auditorium Jean Paul II, Quartier Mbankolo, B.P. 4966, YAOUNDE (CM). (57) The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases. (2Pal); (3Pal) or (4Pal) and
RkJQdWJsaXNoZXIy MTM1NDc3MA==